|
Management of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease |
2.25 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Review of Oral Targeted Therapies in Acute Myeloid Leukemia |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Managing Earlier Integration of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies |
1.00 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Amyloidosis: Diagnosis, Treatment, and Supportive Care |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Diagnosis and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Evaluation and Treatment of Primary Central Nervous System Lymphoma |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Chronic Myeloid Leukemia: How to Treat During Pregnancy |
0.25 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Management of TP53 Mutated Mantle Cell Lymphoma |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
The Role of JAK Inhibitors in the Management of Myelofibrosis |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies |
1.00 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
NCCN Guidelines® Insights - Survivorship, Version 2.2024 |
1.00 |
12/10/2024 - 12:00am to 12/10/2025 - 12:00am |
|
Unraveling Cancer Pain Dynamics |
1.00 |
12/16/2024 - 12:00am to 10/31/2025 - 11:59pm |
|
Patient Management Simulator: Treatment Recommendations for Kidney Cancer with Management of Immunotherapy-Related Toxicities |
|
12/19/2024 - 12:00am to 12/19/2025 - 12:00am |
Facebook
X
LinkedIn
Forward